Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue medicines for difficult targets in ...

Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Orionis announced its first collaboration with Genentech, to discover novel small-molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration ...

Orionis Biosciences, a privately held, clinical-stage life sciences company focused on the rational discovery and development of drug modalities with induced proximity mode of action, today announced ...